BIO-Europe Spring® 2014: The personalized therapy challenge

March 27, 2014
Very few companies have the in-house expertise to understand and identify all of the relevant biomarkers relating to a specific disease target or new therapeutic opportunity. These insights will likely come through external collaborations. One of the key questions facing drug developers today is how to incorporate efficient use of biomarkers into a drug development and clinical program that will help them validate a commercial opportunity. For more information on BIO-Europe Spring, visit our webpage: http://www.ebdgroup.com/bes/index.php Please view the rest of the video at http://www.partnering360.com/insight/showroom/id/483
Previous Video
BIO-Europe Spring® 2014: Pharma steps up early on relevance data
BIO-Europe Spring® 2014: Pharma steps up early on relevance data

For valuations on biotech/pharma deals, one principle has been inviolate: later stage programs, especially ...

Next Video
BIO-Europe Spring® 2014: Who will finance early stage drug discovery?
BIO-Europe Spring® 2014: Who will finance early stage drug discovery?

Common wisdom holds that it is getting harder and harder to find funding for drug discovery—yet financing d...